HOMEPAGE
Fully Diluted Subscribe

Nasdaq · Biotech stocks database

VOR — Vor Biopharma Inc.

VOR (Vor Biopharma Inc.) stock: $20.01, $1.23B market cap, $481.6M cash, $747.7M EV, $2.13B fully diluted market cap. Lead program: Telitacicept (Generalized Myasthenia Gravis), Phase 3. Data from Fully Diluted's biotech stocks database.

What they do

Vor Biopharma, Inc. ("Vor Bio") is a clinical-stage biopharmaceutical company focused on developing a novel therapy in the treatment of autoimmune diseases. In June 2025, we in-licensed telitacicept from RemeGen Co., Ltd. (“RemeGen”).

Source: 10-K FY2025 via SEC EDGAR

Share price
$20.01
Market cap
$1,229.2M
Cash
$481.6M
Enterprise value
$747.7M

Balance sheet

Cash$481.6M
Debt$0.0M
Net cash$481.6M
Enterprise value$747.7M
Basic shares61.4M shares
Fully diluted shares106.3M shares
Fully diluted market cap$2,127.1M
Cash per share$7.84
Quarterly burn$25.4M
Cash runway19.0 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-10.

Share structure

Common
59.2M
Pre-funded warrants
0.0M
Options
7.5M
RSUs
0.4M
Warrants
39.0M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
0.2M
FDSO
106.3M

Cap table as of 2026-08-06.

Price history

Loading VOR daily closes…

Loading price history…

Next catalyst

Telitacicept · Jun 12 - Jul 24 in 7 mo · Phase 3 · Generalized Myasthenia Gravis

Recently reported

Telitacicept Phase 3 Mixed · 2026-10-22
TH-OR111 · primary sjogren's disease
Primary: Annualized estimated glomerular filtration rate (eGFR) slope through 104 weeks (Stage B primary endpoint, Phase 3 TELIGAN trial in IgA nephropathy) — Annualized eGFR slope through 104 weeks was -0.6 mL/min/1.73 m²/year (95% CI: -1.7 to 0.4) for telitacicept versus -5.7 mL/min/1.73 m²/year (95% CI: -7.0 to -4.5) for placebo, representing a between-group difference of 5.1 mL/min/1.73 m²/year (95% CI: 3.5 to 6.7; p<0.001)
· 89% lower risk of confirmed ≥30% eGFR decline (HR 0.11) and 81% lower risk of confirmed ≥40% eGFR decline (HR 0.19) relative to placebo
· No patient in the telitacicept group experienced a prespecified composite kidney failure endpoint event, compared with five in the placebo group, including two who required dialysis
· At Week 104, 24h-UPCR decreased 60.3% from baseline in the telitacicept group compared with a 0.9% increase in the placebo group, representing a reported placebo-adjusted reduction of 60.7%
· At Week 104, 44.0% of telitacicept-treated patients achieved 24h-UPCR <0.5 g/g versus 8.2% in the placebo group
· Serum galactose-deficient IgA1 (Gd-IgA1) decreased 47.79% from baseline with telitacicept, compared with a 19.06% increase with placebo
· TELIGAN enrolled 318 adults randomized 1:1 to telitacicept 240 mg or placebo
Safety: Treatment-emergent adverse events occurred in 95.0% of telitacicept-treated patients and 89.3% of placebo-treated patients; serious adverse events occurred in 8.2% versus 18.2%; overall infections were reported in 67.3% of each group, and serious infections in 1.9% versus 4.4%; injection-site reactions were more frequent with telitacicept (56.0% versus 18.9%), with most mild to moderate in severity
Source release →
Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 718 stocks.
Subscribe to Compounding Ego